# Oral Administration of AlequelTM for Patients With Inflammatory Bowel Disease (IBD)

> **NCT02185183** · PHASE1,PHASE2 · COMPLETED · sponsor: **Hadassah Medical Organization** · enrollment: 22 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** Alequel

## Key facts

- **NCT ID:** NCT02185183
- **Lead sponsor:** Hadassah Medical Organization
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2010-01
- **Final completion:** 2010-01
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2014-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02185183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02185183, "Oral Administration of AlequelTM for Patients With Inflammatory Bowel Disease (IBD)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02185183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*